Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

Watchlist Manager
Zentalis Pharmaceuticals Inc Logo
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Watchlist
Price: 1.52 USD 3.4% Market Closed
Market Cap: 109.2m USD

Wall Street
Price Targets

ZNTL Price Targets Summary
Zentalis Pharmaceuticals Inc

Wall Street analysts forecast ZNTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZNTL is 5.97 USD with a low forecast of 2.22 USD and a high forecast of 10.5 USD.

Lowest
Price Target
2.22 USD
46% Upside
Average
Price Target
5.97 USD
293% Upside
Highest
Price Target
10.5 USD
591% Upside
Zentalis Pharmaceuticals Inc Competitors:
Price Targets
LYEL
Lyell Immunopharma Inc
94% Downside
300896
Imeik Technology Development Co Ltd
30% Upside
ASMB
Assembly Biosciences Inc
99% Upside
ELUT
Elutia Inc
303% Upside
ARGX
argenx SE
33% Upside
IMAB
I-Mab
125% Upside
BAVA
Bavarian Nordic A/S
57% Upside
2487
Cutia Therapeutics
6% Upside

Revenue
Forecast

Revenue Estimate
Zentalis Pharmaceuticals Inc

The compound annual growth rate of Zentalis Pharmaceuticals Inc's revenue for the next 3 years is -41%.

N/A
Past Growth
-41%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Zentalis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Net Income
Forecast

Net Income Estimate
Zentalis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZNTL's stock price target?
Price Target
5.97 USD

According to Wall Street analysts, the average 1-year price target for ZNTL is 5.97 USD with a low forecast of 2.22 USD and a high forecast of 10.5 USD.

What is Zentalis Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
-41%

The compound annual growth rate of Zentalis Pharmaceuticals Inc's revenue for the next 3 years is -41%.

Back to Top